Division of Merck & Co. Inc.
Latest From Schering Corp.
During Supreme Court oral arguments in the AndroGel pay-for-delay case, the government and drug manufacturers each pushed for a one-size-fits-all antitrust interpretation of brand-generic reverse payment settlements. But the most likely outcome will probably fall somewhere in the middle: allowing the deals to continue, but with additional scrutiny to ensure they are not anticompetitive.
India's Patent Office revoked Merck's patent for its asthma drug, based on a challenge by Cipla.
The high court will hear oral arguments on whether sales reps sell drugs or just promote them; Thomas Goldstein, who won a victory for PhRMA in Sorrell v. IMS, is representing the sales reps and former Solicitor General Paul Clement is arguing for GlaxoSmithKline.
Court to decide whether sales reps qualify for overtime pay in case involving former GlaxoSmithKline reps; it is the third pharma case this term.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Merck & Co. Inc.
- Senior Management
Maurice Mezzino, Mgr., New Products
Mark Wiggins, Dir. of Mktg.
- Contact Info
Phone: (305) 698-4600
13900 N.W. 57th Court
Miami Lakes, FL 33014
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.